Susquehanna International Group, LLP Aeterna Zentaris Inc. Call Options Transaction History

Susquehanna International Group, LLP

11 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2022 Aug 15, 2022	BUY	$0.17 - $0.37 $1,173 - $2,553	6,900 Added 11.75%	65,600 $13,000
Q1 2022 May 16, 2022	BUY	$0.33 - $0.42 $14,157 - $18,018	42,900 Added 271.52%	58,700 $22,000
Q4 2021 Feb 14, 2022	SELL	$0.36 - $0.77 $31,428 - $67,221	-87,300 Reduced 84.68%	15,800 $6,000
Q3 2021 Nov 15, 2021	SELL	$0.59 - $0.88 $219,008 - $326,656	-371,200 Reduced 78.26%	103,100 $77,000
Q2 2021 Aug 11, 2021	SELL	$0.83 - $1.14 $174,383 - $239,513	-210,100 Reduced 30.7%	474,300 $416,000
Q1 2021 May 17, 2021	BUY	$0.51 - $3.34 $349,044 - $2.29 Million	684,400 New	684,400 $780,000
Q2 2020 Aug 14, 2020	SELL	$0.45 - $1.2 $4,500 - $12,000	-10,000 Closed	0 $0
Q4 2019 Feb 14, 2020	SELL	$0.77 - $1.08 $12,859 - $18,036	-16,700 Reduced 62.55%	10,000 $9,000
Q3 2019 Nov 14, 2019	BUY	$1.0 - $2.97 $7,900 - $23,463	7,900 Added 42.02%	26,700 $28,000
Q2 2019 Aug 14, 2019	BUY	$2.04 - $5.43 $10,404 - $27,693	5,100 Added 37.23%	18,800 $55,000
Q4 2018 Feb 14, 2019	BUY	$1.3 - $3.87 $17,810 - $53,019	13,700 New	13,700 $40,000

Ticker AEZS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 4,855,880
Market Cap $19.4M
Description
Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing therapeutics and diagnostic tests. Its lead product is macimorelin, an orally available peptidomimetic ghrelin receptor (GHSR-1a) agonist that stimulates the secretion of growth hormone by binding to the GHSR-1a for the diagnosis of adult grow...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.